Overview
Bifunctional enzyme deficiency, also known as D-bifunctional protein deficiency (DBP deficiency) or peroxisomal bifunctional enzyme deficiency, is a severe autosomal recessive disorder of peroxisomal fatty acid beta-oxidation. The condition is caused by mutations in the HSD17B4 gene, which encodes D-bifunctional protein (DBP), an enzyme essential for the peroxisomal beta-oxidation of very-long-chain fatty acids, branched-chain fatty acids (such as pristanic acid), and bile acid intermediates (DHCA and THCA). Deficiency of this enzyme leads to accumulation of these substrates in body tissues and fluids. The disease predominantly affects the central nervous system and presents in the neonatal period with severe hypotonia, seizures (often intractable), failure to thrive, and characteristic craniofacial dysmorphism resembling Zellweger syndrome. Affected infants typically show profound developmental delay, visual impairment, sensorineural hearing loss, and hepatomegaly. Brain MRI often reveals defects in neuronal migration and progressive white matter abnormalities. The clinical spectrum is divided into several subtypes based on which enzymatic activity is deficient (type I: both hydratase and dehydrogenase; type II: hydratase only; type III: dehydrogenase only; type IV: milder phenotype with later onset). The prognosis for the severe neonatal forms is poor, with most affected children dying within the first two years of life. A milder type IV presentation has been described with later-onset cerebellar ataxia, sensorineural hearing loss, and longer survival into adolescence or adulthood. There is currently no curative treatment for bifunctional enzyme deficiency. Management is supportive and symptomatic, including seizure control, nutritional support, physical therapy, and management of hearing and visual impairment. Dietary restriction of phytanic acid and very-long-chain fatty acids has been attempted but has not demonstrated clear clinical benefit in severe forms.
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Bifunctional enzyme deficiency.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Bifunctional enzyme deficiency at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Financial Resources
2 resourcesAmmonul
Medicis Pharmaceutical Corp.
Ammonul — Contact Medicis Pharmaceutical Corp.
Sodium Phenylacetate And Sodium Benzoate
Zydus Pharmaceuticals USA Inc.
Sodium Phenylacetate And Sodium Benzoate — Contact Zydus Pharmaceuticals USA Inc.
Travel Grants
No travel grants are currently matched to Bifunctional enzyme deficiency.
Community
No community posts yet. Be the first to share your experience with Bifunctional enzyme deficiency.
Start the conversation →Latest news about Bifunctional enzyme deficiency
No recent news articles for Bifunctional enzyme deficiency.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Bifunctional enzyme deficiency
What is Bifunctional enzyme deficiency?
Bifunctional enzyme deficiency, also known as D-bifunctional protein deficiency (DBP deficiency) or peroxisomal bifunctional enzyme deficiency, is a severe autosomal recessive disorder of peroxisomal fatty acid beta-oxidation. The condition is caused by mutations in the HSD17B4 gene, which encodes D-bifunctional protein (DBP), an enzyme essential for the peroxisomal beta-oxidation of very-long-chain fatty acids, branched-chain fatty acids (such as pristanic acid), and bile acid intermediates (DHCA and THCA). Deficiency of this enzyme leads to accumulation of these substrates in body tissues an
How is Bifunctional enzyme deficiency inherited?
Bifunctional enzyme deficiency follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Bifunctional enzyme deficiency typically begin?
Typical onset of Bifunctional enzyme deficiency is neonatal. Age of onset can vary across affected individuals.
Which specialists treat Bifunctional enzyme deficiency?
2 specialists and care centers treating Bifunctional enzyme deficiency are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.
What treatment and support options exist for Bifunctional enzyme deficiency?
2 patient support programs are currently tracked on UniteRare for Bifunctional enzyme deficiency. See the treatments and support programs sections for copay assistance, eligibility, and contact details.